Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 8/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002798 | 0.86 | DRD3 (0.65) | DRD3HTR1A | |
| SCHEMBL19049383 | 0.86 | DRD3 (0.45) | DRD3PDE2ASCD5USP30NAMPT | |
| SCHEMBL2294363 | 0.86 | LMNA (0.52) | DRD3PDE2AGRIN2B | |
| SCHEMBL2295935 | 0.86 | LMNA (0.52) | DRD3PDE2AGRIN2B | |
| SCHEMBL19002795 | 0.85 | DRD3 (0.48) | DRD3EPHX2PDE2AUSP30NPC1 | |
| SCHEMBL4598876 | 0.85 | SCD5 (0.44) | DRD3PDE2ASCD5USP30NAMPT | |
| SCHEMBL3369775 | 0.85 | SCD5 (0.44) | DRD3PDE2ASCD5USP30NAMPT | |
| SCHEMBL19002793 | 0.85 | MEN1 (0.46) | DRD3EPHX2PDE2ANAMPTMEN1 | |
| SCHEMBL3375799 | 0.85 | SCD5 (0.44) | DRD3PDE2ASCD5USP30NAMPT | |
| SCHEMBL14035660 | 0.84 | USP30 (0.51) | DRD3EPHX2USP30RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | DRD3 4860/4885EPHX2 2625/4885PDE2A 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.